Welcome to medications.com

Risperdal Consta Information

What's inside Risperdal Consta

Risperdal Consta Active Ingredients: risperidone, details.
Risperdal Consta Dosages & Strengths
Strength Format Route Strength Class
Risperdal Consta 25 mg/2 weeks powder for injection, extended release intramuscular 1.0 each OTC
Risperdal Consta 37.5 mg/2 weeks powder for injection, extended release intramuscular 1.0 each OTC
Risperdal Consta 50 mg/2 weeks powder for injection, extended release intramuscular 1.0 each OTC

Risperdal Consta in the News

Study finds IONSYS (TM), a New Needle-Free System for Management ... - ITNews
... behavioural psychological symptoms of dementia, disruptive behaviour disorders, autism) and RISPERDAL(R), CONSTA(TM) (schizophrenia). ...
Tue Mar 04 01:02:18 -0500 2008

Study finds IONSYS (TM), a New Needle-Free System for Management ... - ITNews
... behavioural psychological symptoms of dementia, disruptive behaviour disorders, autism) and RISPERDAL(R), CONSTA(TM) (schizophrenia). ...
Tue Mar 04 01:02:18 -0500 2008

FDA rejects injectable Zyprexa - Indianapolis Star
That version of the drug, Risperdal Consta, is manufactured by Alkermes and already has achieved blockbuster status by exceeding $1.1 billion in annual ...
Fri Feb 29 02:50:26 -0500 2008


Risperdal Consta Chemical Information

risperidone - A benzisoxazole derivative with antipsychotic property. Risperidone selectively antagonizes serotonin (5-HT) effects via cortical 5-HT2 receptor, and, to a lesser extent, competes with dopamine at the limbic dopamine D2 receptor. The antagonism leads to decreased psychotic effects, such as hallucinations and delusions. In addition, risperidone has low to moderate affinity for histamine H1, 5-HT1A, 5-HT1C, and 5-HT1D receptors, while it has weak affinity for dopamine D1 and haloperidol-sensitive sigma site receptors.



Related Drugs
Related drugs contain similar ingredients


Risperdal Consta Videos

© 2002-2007, Skylabs Inc.  |  About Us  |  Disclaimer/Terms of Use  |  Advertise  |  Contact Us  |  Site Map  |  Developed by: W3matter.com